Alvelestat - AstraZeneca/Mereo BioPharma

Drug Profile

Alvelestat - AstraZeneca/Mereo BioPharma

Alternative Names: AZD-9668

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer Allegheny Singer Research Institute; AstraZeneca; National Cancer Institute (USA)
  • Class Amides; Bronchodilators; Pyrazoles; Pyridines
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Phase I/II Bronchiolitis obliterans
  • Discontinued Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 20 Nov 2017 Chemical structure added
  • 30 Oct 2017 Mereo Biopharma plans a phase II trial for Alpha-1 antitrypsin deficiency (PO) in 2018
  • 30 Oct 2017 Alvelestat is licensed to Mereo BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top